Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,143.66 +64.80 (+0.80%) Bitcoin USD
64,003.54 +634.49 (+1.00%) CMC Crypto 200
1,340.18 -56.35 (-4.03%)
Longeveron Inc. (LGVN)
| Previous close | 1.6700 |
| Open | 1.6700 |
| Bid | 1.6100 x 100 |
| Ask | 1.7100 x 100 |
| Day's range | 1.6202 - 1.7200 |
| 52-week range | 1.6000 - 44.0000 |
| Volume | |
| Avg. volume | 2,108,421 |
| Market cap | 8.109M |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -10.2000 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 30.05 |
GlobeNewswireLongeveron to Present at the Planet MicroCap Showcase
MIAMI, April 25, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Planet MicroCap Showcase, taking place May 1-2, 2024. Details for the Company’s presentation: Date:Wednesday, May 1, 2024 Time:4:30 p.m. PT Webcast:Click Here An archived replay of the webcast will be available on the “Events & Presentations” section of the Company’s website following the conference. If
- GlobeNewswire
Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering
MIAMI, April 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, today announced the closing of its previously announced exercise of certain existing warrants to purchase an aggregate of 2,399,744 shares of its Class A common stock havin
- GlobeNewswire
Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds
MIAMI, April 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 2,399,744 shares of its Class A com
